• The global AI in drug-discovery market was valued at approximately $3.25 billion in 2026 and is projected to reach more than $10 billion by 2031.
• Oncotelic’s central technology, the PDAOAI platform, was designed from the outset to be something more than a research accelerator for internal programs.
• The most significant development to date came when Oncotelic announced the successful integration of approximately 28 million scientific abstracts, into its PDAOAI platform.

Artificial intelligence is no longer a buzzword in the life sciences; rather, it is rapidly becoming the defining infrastructure layer of modern drug development. The companies that control the most intelligent platforms may ultimately control the industry’s future. Among the clinical-stage players quietly positioning themselves at the center of this shift is Oncotelic Therapeutics (OTCQB: OTLC), a California-based oncology company that has spent years building a proprietary AI platform and is now turning that platform into something more ambitious than a drug-discovery tool.

The broader market context makes Oncotelic’s strategy worth taking seriously. The global AI in drug-discovery market was valued at approximately $3.25 billion in 2026 and is projected to grow at a compound annual growth rate of roughly 26% through 2031, reaching over $10 billion. Oncology, notably, is the leading therapeutic segment within that market, accounting for the largest revenue share among all disease areas as of 2025.

This puts Oncotelic at the intersection of two powerful forces: the explosive commercial potential of AI-driven platforms and the urgent, ongoing need for better cancer therapies. The question investors and industry observers are beginning to ask is not whether AI belongs in drug development — that debate is settled — but rather whether a lean, clinical-stage biotech can build a platform sophisticated enough to compete with, and license to, the giants of the pharmaceutical world.

The case that small players can out-innovate big pharma is not merely theoretical. As of early 2026, more than 270 pharmaceutical and biotechnology companies globally have active AI drug discovery programs, up from fewer than 80 in 2020. Meanwhile, the volume of partnering deals between AI platform companies and large pharma has increased by more than 340% over that same five-year period. 

The acceleration reflects a structural reality: Large pharmaceutical companies are buyers and partners as much as they are builders, and startups and clinical-stage biotechs with validated, proprietary platforms have an opening to define themselves as indispensable infrastructure providers.

Oncotelic’s central technology, the PDAOAI platform, was designed from the outset to be something more than a research accelerator for internal programs. The platform embeds, clusters and queries large biomedical datasets to surface citation-backed, testable hypotheses, without training bespoke large language models on proprietary data, a distinction that carries meaningful regulatory and intellectual property implications. 

In late 2025, Oncotelic opened public access to PDAOAI through a dedicated Discord research channel, publishing a curated TGF-β literature corpus of more than 125,000 PubMed abstracts, a move that simultaneously demonstrated scientific transparency and showcased the platform’s capacity to organize and interrogate the scientific literature at scale. The company’s TGF-β2 program, advanced through its lead candidate OT-101, has been a cornerstone of Oncotelic’s clinical pipeline for years, but PDAOAI now gives that work a technological backbone that could make the platform itself as valuable as any single drug candidate.

The most significant development to date came in late April 2026, when Oncotelic announced the successful integration of approximately 28 million scientific abstracts, described by the company as representing the totality of scientific knowledge, into its PDAOAI platform. This integration was not merely a data ingestion exercise. The milestone enabled real-time application of that knowledge base within a jointly developed robotics platform built in partnership with TechForce Robotics Inc., allowing scientific knowledge to be directly embedded into automated workflows operating in regulated pharmaceutical environments. The combined platform is designed to improve operational efficiency, reduce reliance on manual processes, and support compliance across pharmaceutical development and manufacturing, capabilities that speak directly to some of the most stubborn cost and risk challenges in drug manufacturing today.

The pattern that emerges from Oncotelic’s recent trajectory is one of a company that has systematically converted scientific and technical development into a commercial platform without losing sight of its clinical mission. AI in biotech is entering a phase where success will be defined less by novel algorithms and more by whether organizations can move from experimentation to dependable infrastructure, systems that are interpretable to scientists and defensible to regulators. 

With 28 million abstracts powering its robotics platform, a GMP-compliant deployment partnership in place and an oncology pipeline actively generating clinical data, Oncotelic appears to be doing exactly that. For investors and industry watchers asking whether a small clinical-stage player can out-innovate big pharma, Oncotelic Therapeutics is building its answer one integration milestone at a time.

Public-market examples such as Sangamo Therapeutics, Inc. (OTCQB: SGMO), CytoDyn Inc. (OTCQB: CYDY), Netlist, Inc. (OTCQB: NLST), and NorthWest Biotherapeutics, Inc. (OTCQB: NWBO) demonstrate continued investor appetite for platform-driven companies built around proprietary technology ecosystems, infrastructure-layer intellectual property, and long-duration scientific optionality beyond any single product candidate.

For more information, visit the company’s website at www.Oncotelic.com.

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at ibn.fm/OTLC

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN